ArticleDiscover oncology2026
M2 macrophage related genes predict prognosis and drug response in prostate cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundM2 macrophages significantly contribute to the advancement of prostate cancer (PCa). This research aims to pinpoint M2 macrophage-associated genes (M2RGs) by leveraging single-cell analyses, with a focus on evaluating their prognostic and therapeutic implications in PCa.
methodsWe utilized transcriptomic and scRNA-seq datasets sourced from GEO and TCGA, analyzing both PCa and nearby non-cancerous tissues. M2 macrophage infiltration levels were quantified through “Cibersort” and “xCell” algorithms, followed by assessing their relationship with PCa outcomes. We identified M2RGs using differential expression analysis from scRNA-seq data. A risk score model (M2GS) was subsequently developed using COX and LASSO regression to predict biochemical recurrence-free survival (BRFS) and drug sensitivity. ROC curve analysis and subgroup assessments were conducted to evaluate model performance. Additionally, a nomogram integrating M2GS and clinical parameters was created to refine prediction accuracy.
resultsHigher infiltration levels of M2 macrophages were linked to poorer outcomes in patients with prostate cancer (PCa). Using COX regression and LASSO analyses, we identified seven M2 macrophage-related genes (M2RGs) with prognostic significance: MTUS1, NFE2L2, CD9, NOP56, KIF22, RBM3, and RALGDS, which were incorporated into an M2-related gene signature (M2GS). ROC analysis affirmed the model’s predictive capabilities, yielding AUC values of 0.702, 0.752, and 0.831 for predicting 1-, 3-, and 5-year survival, respectively. Subgroup analysis and violin plot comparisons highlighted distinct drug sensitivity patterns between high- and low-risk groups defined by M2GS. Both M2GS and T stage were independently validated as prognostic indicators. The nomogram demonstrated consistent calibration and strong predictive performance.
conclusionOur prognostic risk scoring model effectively predicts BRFS and drug responsiveness in prostate cancer, providing clinicians with valuable guidance for tailoring individualized treatment strategies and follow-up protocols for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.